Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.48 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824432 | 0.91 | ANPEP (0.55) | ANPEPRNPEPDNPEPEPHX1RAB9A | |
| SCHEMBL11105386 | 0.84 | EPHX1 (0.58) | EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL26930838 | 0.83 | EPHX1 (0.63) | ANPEPRNPEPDNPEPEPHX1SMN1; SMN2 | |
| SCHEMBL10224058 | 0.82 | EPHX1 (0.60) | ANPEPRNPEPDNPEPEPHX1RAB9A | |
| SCHEMBL11151073 | 0.80 | ANPEP (0.47) | ANPEPRNPEPDNPEPEPHX1RAB9A | |
| SCHEMBL23173031 | 0.80 | EPHX1 (0.52) | EPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL14521021 | 0.79 | EPHX1 (0.73) | EPHX1SMN1; SMN2EPHX2CNR1 | |
| SCHEMBL7751971 | 0.79 | ANPEP (0.50) | ANPEPRNPEPDNPEPEPHX1RAB9A | |
| SCHEMBL15248051 | 0.78 | CNR1 (0.51) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL12787079 | 0.77 | EPHX1 (0.57) | ANPEPRNPEPDNPEPEPHX1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| US-9516880-B2 | Herbicidal and fungicidal 5-oxy-substituted 3-phenylisoxazoline-5-carboxamides and 5-oxy-substituted 3-phenylisoxazoline-5-thioamides | BAYER CROPSCIENCE AG (DE) | 2016-12-13 | — | — | US | disclosed |
| US-9516880-B2 | Herbicidal and fungicidal 5-oxy-substituted 3-phenylisoxazoline-5-carboxamides and 5-oxy-substituted 3-phenylisoxazoline-5-thioamides | BAYER CROPSCIENCE AG (DE) | 2016-12-13 | — | — | US | disclosed |
| US-20150245616-A1 | HERBICIDAL AND FUNGICIDAL 5-OXY-SUBSTITUTED 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 5-OXY-SUBSTITUTED 3-PHENYLISOXAZOLINE-5-THIOAMIDES | BAYER CROPSCIENCE AG (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150245616-A1 | HERBICIDAL AND FUNGICIDAL 5-OXY-SUBSTITUTED 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 5-OXY-SUBSTITUTED 3-PHENYLISOXAZOLINE-5-THIOAMIDES | BAYER CROPSCIENCE AG (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150223461-A1 | HERBICIDALLY AND FUNGICIDALLY ACTIVE 3-HETEROARYL-ISOXAZOLINE-5-CARBOXAMIDES AND 3-HETEROARYL-ISOXAZOLINE-5-THIOAMIDES | BAYER CROPSCIENCE AG (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20150223461-A1 | HERBICIDALLY AND FUNGICIDALLY ACTIVE 3-HETEROARYL-ISOXAZOLINE-5-CARBOXAMIDES AND 3-HETEROARYL-ISOXAZOLINE-5-THIOAMIDES | BAYER CROPSCIENCE AG (DE) | 2015-08-13 | — | — | US | disclosed |
| US-8933077-B2 | Glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20100056530-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150223461-A1 | HERBICIDALLY AND FUNGICIDALLY ACTIVE 3-HETEROARYL-ISOXAZOLINE-5-CARBOXAMIDES AND 3-HETEROARYL-ISOXAZOLINE-5-THIOAMIDES | CBR3, CYP3A7, PRDX3 | ANPEP 2029/4885RNPEP 2345/4885DNPEP 2174/4885 |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | ANPEP 292/4885RNPEP 413/4885DNPEP 520/4885 |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | ALK, NPM1, EML4 | ANPEP 120/4885RNPEP 822/4885DNPEP 459/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | ANPEP 2320/4885RNPEP 1079/4885DNPEP 1122/4885 |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | ANPEP 2925/4885RNPEP 2828/4885DNPEP 2208/4885 |
| US-20100056530-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | ANPEP 3111/4885RNPEP 1401/4885DNPEP 1835/4885 |
| US-20150245616-A1 | HERBICIDAL AND FUNGICIDAL 5-OXY-SUBSTITUTED 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 5-OXY-SUBSTITUTED 3-PHENYLISOXAZOLINE-5-THIOAMIDES | CYP4X1, PRDX4, PRDX5 | ANPEP 2324/4885RNPEP 2846/4885DNPEP 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.